---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-026579"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T15:54:05.853918+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vericel Q2 revenue $45.9M (+24% YoY); raises FY2023 guidance to $190-197M

## Summary
- Total net revenue $45.9M (+24% YoY); MACI $36.3M (+27%), Epicel $9.6M (+17%).
- Net loss $5.0M ($0.11 EPS) improved from $9.0M loss in Q2 2022; adjusted EBITDA $4.4M.
- Full-year 2023 revenue guidance raised to $190-197M from prior $184-192M; gross margin guidance high-60% maintained.
- MACI arthroscopic delivery program on track for 2024 commercial launch; human factors study planned Q3.
- Extended exclusive supply agreement with Matricel GmbH for MACI collagen membrane.

## SEC filing metadata
- accession: 0001628280-23-026579
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828023026579/0001628280-23-026579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828023026579/vcel-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-026579
- JSON: https://secwatch.observer/filing/0001628280-23-026579.json
- Plain text: https://secwatch.observer/filing/0001628280-23-026579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.